Skip to main content
SP5007,675.51-0.47%DOW53,233.85-0.61%NASDAQ26,277.36-0.47%BTC$78,436.00-0.44%ETH$2,463.87-0.54%GOLD$4,483.70-1.02%OIL$85.40+2.40%
Smart Investors Daily
Sign InSign Up Free
ON

NASDAQ · ONC

BeOne Medicines Ltd.

Healthcare · Medical - Pharmaceuticals

$366.73

Down-$10.37 (-2.83%)

Updated Aug 31, 2026, 2:19 PM

SID Score

6.2/10

Composite research score

Smart Money

56/100

Neutral

Market cap
34.25B
P/E ratio
-21.14
Dividend yield
0.00%
52-week range
$253.95 – $385.22
Volume
341.59K
Avg. volume
259.1K

Price performance

ONC price history

1M range · 20 trading sessions · Daily adjusted prices

ONC closed at $366.73 after 20 trading sessions, up 16.88% for the selected period.

Last close
$366.73
Period change
+16.88%
Period low
$313.77
Period high
$376.86
Daily close
View OHLC price history
ONC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 28, 2026$369.13$372.00$364.73$366.73341.59K
Aug 27, 2026$372.35$374.94$371.51$372.49225.07K
Aug 26, 2026$376.27$377.66$372.01$375.80125.83K
Aug 25, 2026$370.12$380.00$369.49$376.37396.29K
Aug 24, 2026$369.53$372.825$365.14$371.98351.54K
Aug 21, 2026$375.00$379.48$374.37$374.47252.6K
Aug 20, 2026$372.55$376.00$368.82$369.16311.75K
Aug 19, 2026$371.56$379.20$371.05$376.86379.9K
Aug 18, 2026$364.00$370.80$361.1401$369.15613.55K
Aug 17, 2026$354.31$362.98$353.9775$362.51465.42K
Aug 14, 2026$350.55$352.51$343.50$347.48382.88K
Aug 13, 2026$358.54$360.61$354.2275$356.01355.46K
Aug 12, 2026$355.61$359.785$353.3377$359.05314.91K
Aug 11, 2026$360.00$366.99$358.66$359.27634.93K
Aug 10, 2026$351.20$361.33$349.90$359.00833.36K
Aug 7, 2026$345.47$349.88$341.865$348.27638.2K
Aug 6, 2026$330.27$333.87$326.13$329.80279.84K
Aug 5, 2026$329.00$333.01$327.13$327.53476.55K
Aug 4, 2026$321.00$324.48$314.55$323.01385.28K
Aug 3, 2026$316.01$316.01$309.935$313.77359.52K

Latest ONC news

The latest Smart Investors Daily articles mentioning ONC.

Stock researchCompany · Overview

ONC research

Overview

Company profile and research snapshot.

Company profile

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$397.00
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 25, 2026

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

SAN CARLOS, Calif., August 25, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction,

Yahoo · Aug 18, 2026

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

SAN CARLOS, Calif. & SEATTLE, August 18, 2026--BeOne Medicines Ltd. ("BeOne") (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with t

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By